SecBot SecBot

BLTE

BELITE BIO, INC
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001889109 Biotech & Drug Discovery
$147.33 −2.94 (−1.96%)
Oct 23 4:00 PM ET · prev $150.27
Market cap
$6.1B
Mid cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
🔒 Subscribers only
1 year
+58.7%
from $92.82 · Oct 24
30 days
−13.0%
from $169.44
52-week range
$92.82–193.61
−24% from high · low Oct 24
Avg volume 20D
165.0K
shares / day
Short interest
1.06M
≈2.6% of shares · +0.7%
Days to cover
7.3
at average volume
Insider net
-$32.1M
0 buyers · 3 sellers · since Aug 12
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/4 ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL Belite Bio announced it has received approval to transfer its listing from the Nasdaq Capital Market to the…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $32.1M.

  • InstitutionsMIXED

    Q2 2026: 11 added (1 new), 10 trimmed or exited. Largest new: Maverick Capital $61.0M.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +0.7% to 1.06M shares. 7.3 days to cover, ≈2.6% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$61.0M
in new stakes
FundMoveSharesValue
MAVERICK CAPITAL LTDNEW396,311$61.0M
Holocene Advisors, LPTRIM251,035$38.7M
UBS Group AGTRIM224,989$34.6M
CITADEL ADVISORS LLCDOUBLED186,168$28.7M
GOLDMAN SACHS GROUP INCADD166,188$25.6M
BANK OF AMERICA CORP /DE/DOUBLED124,783$19.2M
PRICE T ROWE ASSOCIATES INC /MD/TRIM105,859$16.3M
JANE STREET GROUP, LLCDOUBLED65,801$10.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy10Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 9, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Sep 8, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 4, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Aug 14, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Aug 14, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$32.1M
sold · 3 insiders
DateInsiderTypeValue
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$340.04
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$2.4K
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$2.0K
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$13.1K
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$8.3K
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$19.9K
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$32.7K
Oct 1, 2026
Scholl Hendrik Peter
Chief Medical Officer
SELL$4.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,057,536
shares short
+0.7%
vs prior settlement
7.3
days to cover
≈2.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Belite Bio announced it has received approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq…
6-K — Impact 4/10
Oct 19, 2026 Other
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “C
Oct 1, 2026 Insider
Scholl Hendrik Peter sold 2 shares
Chief Medical Officer @ $170.02 ($340.04)
Oct 1, 2026 Insider
Scholl Hendrik Peter sold 14 shares
Chief Medical Officer @ $169.36 ($2.4K)
Oct 1, 2026 Insider
Scholl Hendrik Peter sold 12 shares
Chief Medical Officer @ $168.21 ($2.0K)
Sep 10, 2026 SEC
CEO and CFO of Belite Bio sold a combined $837K in open-market sales on Sept 4, 2026, part of a larger 7-day cluster…
CLUSTER — Impact 6/10
Aug 13, 2026 SEC
Belite Bio reported Q2 2026 financial results alongside the key catalyst that the FDA accepted its NDA with Priority…
6-K — Impact 7/10
Jun 30, 2026 Inst.
MAVERICK CAPITAL LTD — NEW
396,311 shares ($61.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 19, 2026
Press release
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development…
Sep 29, 2026
Press release
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development…
Sep 8, 2026
Press release
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug…
Sep 1, 2026
Press release
Belite Bio to Participate in Four Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development…
Aug 24, 2026
Press release
Belite Bio to Host Virtual Commercial Day on September 2, 2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development…

SecBot reports

10 filings · 1 press releases · 4 bullish · 3 bearish · 1 mixed · 2 neutral
All BLTE filing & press-release reports (11)